PolyPid
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 62
- Market Cap
- -
- Website
- http://www.polypid.com
- Introduction
PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.
Clinical Trials
22
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
- Conditions
- Surgical Site InfectionColon SurgeryAbdominal SurgeryPost-Op Infection
- Interventions
- Other: Standard of Care (SoC)
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- PolyPid Ltd.
- Target Recruit Count
- 800
- Registration Number
- NCT04411199
- Locations
- 🇺🇸
Augusta Univeristy, Augusta, Georgia, United States
🇺🇸Ochsner Medical Center, New Orleans, Louisiana, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
- Conditions
- Surgical Site InfectionColon SurgeryPost-Op InfectionAbdominal Surgery
- Interventions
- Other: Standard of Care (SoC)
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- PolyPid Ltd.
- Target Recruit Count
- 977
- Registration Number
- NCT04233424
- Locations
- 🇺🇸
Shoals Medical Trials, Sheffield, Alabama, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Paradigm Clinical Research Center, Redding, California, United States
D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
- Conditions
- Colon SurgeryAbdominal SurgeryPost-Op Infection
- Interventions
- Other: Standard of Care (SoC)Drug: D_PLEX
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- PolyPid Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT03633123
- Locations
- 🇮🇱
Wolfson MC, Holon, Israel
🇮🇱Meir MC, Kfar Saba, Israel
🇮🇱Rabin MC, Campus Beilinson, Petach Tikva, Israel
D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery
- Conditions
- Surgical Site InfectionCardiac SurgerySternal Infection
- Interventions
- Other: Standard of Care
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- PolyPid Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT03558984
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Memorial Hermann, Houston, Texas, United States
🇮🇱Soroka Medical Center, Beer Sheva, Israel
Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery
- Conditions
- Postoperative Wound Infection Superficial IncisionalPostoperative Wound Infection Deep Incisional Surgical Site
- Interventions
- Procedure: Open heart surgery
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- PolyPid Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT02731573
- Locations
- 🇮🇱
Soroka Medical Center, Beer sheva, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
🇮🇱Assuta Medical Center, Tel Aviv, Israel
- Prev
- 1
- 2
- Next
News
PolyPid's D-PLEX100 Poised for Potential 2026 Launch After SHIELD II Trial Update
PolyPid's SHIELD II Phase 3 trial for D-PLEX100, targeting surgical site infections, is set to conclude enrollment at 800 patients following DSMB recommendation.
PolyPid's D-PLEX100 Phase 3 Trial Advances with Positive DSMB Recommendation and $41 Million Financing
PolyPid's SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgeries, will continue enrollment to 800 patients.
PolyPid Faces Nasdaq Non-Compliance Amidst Anticipation for Phase 3 Trial Results
PolyPid has received a Nasdaq notification for failing to meet the minimum stockholders' equity requirement, reporting $2.158 million against the required $2.5 million.
PolyPid's SHIELD II Trial for D-PLEX100 Nears Completion, Interim Analysis Expected Soon
PolyPid's SHIELD II trial, evaluating D-PLEX100 for surgical site infection prevention in colorectal surgeries, anticipates full enrollment by December 2024.
PolyPid's SHIELD II Trial Progresses Amid Q3 Results
PolyPid reported its Q3 results, highlighting the ongoing progress of the SHIELD II trial, which is evaluating a novel approach to surgical site infection prevention.
PolyPid's D-PLEX100 SHIELD II Trial Completes Patient Enrollment for Interim Analysis
PolyPid has completed enrollment of 430 patients in the SHIELD II Phase 3 trial of D-PLEX100, triggering an unblinded interim analysis.
PolyPid Gains Momentum with Positive Phase 3 Outlook for D-PLEX100
PolyPid's stock is gaining traction following a Buy rating from Craig-Hallum, driven by promising Phase 3 data expectations for D-PLEX100 in preventing surgical site infections (SSI).
PolyPid's D-PLEX100 Phase 3 Trial Reaches Interim Analysis Milestone
PolyPid has completed enrollment for the unblinded interim analysis of its SHIELD II Phase 3 trial of D-PLEX100.